180 related articles for article (PubMed ID: 36795147)
1. Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study.
Montini F; Nozzolillo A; Rancoita PMV; Zanetta C; Moiola L; Cugnata F; Esposito F; Rocca MA; Martinelli V; Filippi M
J Neurol; 2023 Apr; 270(4):1835-1842. PubMed ID: 36795147
[TBL] [Abstract][Full Text] [Related]
2. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year study.
Montini F; Nozzolillo A; Tedone N; Mistri D; Rancoita PM; Zanetta C; Mandelli A; Furlan R; Moiola L; Martinelli V; Rocca MA; Filippi M;
J Neurol Neurosurg Psychiatry; 2024 Mar; 95(4):342-347. PubMed ID: 37857497
[TBL] [Abstract][Full Text] [Related]
4. Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis.
Dillon P; Siadimas A; Roumpanis S; Fajardo O; Fitovski K; Jessop N; Whitley L; Muros-Le Rouzic E
Mult Scler Relat Disord; 2023 Mar; 71():104512. PubMed ID: 36716576
[TBL] [Abstract][Full Text] [Related]
5. Frequency and characteristics of falls in people living with and without multiple sclerosis during the COVID-19 pandemic: A cross-sectional online survey.
Zanotto T; Frechette ML; Koziel SR; Hsieh KL; Sosnoff JJ
Mult Scler Relat Disord; 2021 Sep; 54():103111. PubMed ID: 34303279
[TBL] [Abstract][Full Text] [Related]
6. Vaccine hesitancy among people with multiple sclerosis.
Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
[TBL] [Abstract][Full Text] [Related]
7. Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies.
Kulikowska J; Czarnowska A; Gudowska-Sawczuk M; Kulczyńska-Przybik A; Bazylewicz M; Collins F; Chorąży M; Mroczko B; Kochanowicz J; Kapica-Topczewska K; Kułakowska A
Neurol Neurochir Pol; 2023; 57(1):121-130. PubMed ID: 36421067
[TBL] [Abstract][Full Text] [Related]
8. A year with the fear of COVID-19 in multiple sclerosis patients: Examination of depression, sleep quality and quality of life before and after the pandemic.
Yeni K; Tulek Z; Terzi M
Mult Scler Relat Disord; 2022 Jan; 57():103370. PubMed ID: 35158434
[TBL] [Abstract][Full Text] [Related]
9. Depression, anxiety, and fear of COVID-19 in patients with multiple sclerosis in pandemic era: a cross-sectional study.
Alirezaei M; Eskandarieh S; Sahraian MA; Naser Moghadasi A
Neurol Sci; 2022 Jan; 43(1):59-66. PubMed ID: 34554334
[TBL] [Abstract][Full Text] [Related]
10. A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.
Ponzano M; Schiavetti I; Bovis F; Landi D; Carmisciano L; De Rossi N; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Bragadin MM; Cocco E; Scandellari C; Cavalla P; Pesci I; Confalonieri P; Perini P; Bergamaschi R; Inglese M; Petracca M; Trojano M; Tedeschi G; Comi G; Battaglia MA; Patti F; Fragoso YD; Sen S; Siva A; Karabudak R; Efendi H; Furlan R; Salvetti M; Sormani MP
Mult Scler Relat Disord; 2022 Jul; 63():103909. PubMed ID: 35675744
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapies.
Beesley R; Cauchi M; Davies L; Upcott M; Norton E; Loveless S; Anderson V; Wynford-Thomas R; Pickersgill TP; Uzochukwu E; Wardle M; Robertson NP; Tallantyre E; Willis MD
Mult Scler Relat Disord; 2022 Dec; 68():104121. PubMed ID: 36088727
[TBL] [Abstract][Full Text] [Related]
12. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
[TBL] [Abstract][Full Text] [Related]
13. Serum vitamin d inversely correlates with depression scores in people with multiple sclerosis.
El-Salem K; Khalil H; Al-Sharman A; Al-Mistarehi AH; Yassin A; Alhayk KA; Qawasmeh MA; Bashayreh SY; Kofahi RM; Obeidat AZ
Mult Scler Relat Disord; 2021 Feb; 48():102732. PubMed ID: 33422916
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada.
Solomon JM; Jones A; Hohol M; Krysko KM; Muccilli A; Roll A; Rotstein D; Schneider R; Selchen D; Vosoughi R; Baral SD; Oh J
Mult Scler Relat Disord; 2022 Feb; 58():103509. PubMed ID: 35030366
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East.
Alroughani R; Inshasi J; Al-Hashel J; Alkhaboury J; Alsalti A; Al Suwaidi R; Hassino LH; Farouk Ahmed S
J Clin Neurosci; 2022 May; 99():311-316. PubMed ID: 35339046
[TBL] [Abstract][Full Text] [Related]
16. Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden.
Teni FS; Machado A; Murley C; He A; Fink K; Gyllensten H; Glaser A; Alexanderson K; Hillert J; Friberg E
Mult Scler Relat Disord; 2023 Jan; 69():104456. PubMed ID: 36529068
[TBL] [Abstract][Full Text] [Related]
17. Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study.
Vogel AC; Schmidt H; Loud S; McBurney R; Mateen FJ
Mult Scler Relat Disord; 2020 Nov; 46():102512. PubMed ID: 32977074
[TBL] [Abstract][Full Text] [Related]
18. Using qualitative free-text data to investigate the lived experience of the COVID-19 pandemic for a large cohort of Australians with different multiple sclerosis related disability levels.
Campbell JA; van der Mei I; Taylor BV; Palmer AJ; Henson GJ; Laslett LL; Simpson-Yap S; Claflin SB
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):975-983. PubMed ID: 37884346
[TBL] [Abstract][Full Text] [Related]
19. Use of natural medicine and dietary supplements concomitant with conventional medicine among people with Multiple Sclerosis.
Bergien SO; Petersen CM; Lynning M; Kristiansen M; Skovgaard L
Mult Scler Relat Disord; 2020 Sep; 44():102197. PubMed ID: 32531752
[TBL] [Abstract][Full Text] [Related]
20. Quantifying the impact of upper limb tremor on the quality of life of people with multiple sclerosis: a comparison between the QUEST and MSIS-29 scales.
Tang CC; Soh SE; Boonstra F; Noffs G; Kolbe SC; Butzkueven H; Evans A; Van der Walt A
Mult Scler Relat Disord; 2022 Feb; 58():103495. PubMed ID: 35085981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
